Association of Psychological Distress in Patients With Lung Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: immunotherapy, Targeted Therapy Agent.
- Who it may be relevant to
- Registry conditions: Lung Neoplasms, Psychological Distress, Prognosis Factors, Lifestyle, Healthy. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
the Association of Psychological Distress in Patients With Advanced Lung Cancer Treated With Immunotherapy or Targeted Therapy
Overview
Psychological distress is a multi-factorial experience of a psychological, social, spiritual, and/or physical nature that may interfere with one's ability to cope effectively with cancer, physical symptoms and treatment. Psychological distress is common and affects the efficacy and prognosis of patients with lung cancer. The systematic anti-tumor therapy may effectively relieve psychological distress including anxiety, depression, and fatigue in patients with advanced lung cancer, the relief of the psychological distress can in turn improve the therapeutic effect. In summary, this study is to explore the associations of (dynamic) psychological stress with the efficacy and survival of anti-tumor therapy including immunotherapy and targeted therapy for advanced lung cancer patients.
Interventions
- Drug immunotherapy
- Drug Targeted Therapy Agent
Primary outcome measures
- Objective response rate (ORR) [Time frame: 20 years]
- Disease control rate (DCR) [Time frame: 20 years]
- Progression-free survival (PFS) [Time frame: 20 years]
Secondary outcome measures (1)
- Overall survival (OS) [Time frame: 20 years]
Eligibility criteria
Inclusion criteria
- Histologically proven diagnosis of lung cancer
- 18 years of age or older
- Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
- Not willing to participate in this clinical trial
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Case-only
Study locations
China · 1 center
- Shanghai Chest Hospital — Shanghai
Identifiers
NCT: NCT06218901 · THORACIC005